| Contact Us | Free Donuts | Search the Site | Sitemap | Workroom | |
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
 |
|
|||||||||
|
|
|||||||||
 |
|
|||||||||
|
Investor Relations Sunesis Threshold United Commercial Bank (UCBH) Netflix Fair, Isaac Chiron Onyx Barra Solectron PeopleSoft ALZA Caliper Technologies Aradigm ProBusiness Protein Design Labs Union Bank Foundation Sangamo BioSciences The Asia Foundation The California Endowment BioTime |
Aradigm had realized several significant accomplishments in 2003. The primary business story was their acquisition of a second novel drug delivery platform that doubled their opportunities for creating novel prescription therapies for acute and chronic conditions. "Doubling Our Opportunities" became the theme to both introduce Intraject—a needle-free injection platform—and to reinforce the company's commitment to, and advances in, its inhaled aerosolized therapy, AERx. Aradigm 2004 Annual Report Aradigm 2004 Annual Report - Online Aradigm 2003 Annual Report - Online Aradigm 2002 Annual Report Aradigm 2002 Annual Report - Online About Aradigm |
|
||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||
|
||||||||||